Open Orphan PLC #ORPH – Venn Life Sciences contract wins
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce its subsidiary Venn Life Sciences (“Venn”) has been awarded two new contracts. The first contract, which will commence immediately, is a COVID-19 […]
Open Orphan #ORPH – Full Year Results
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models is pleased to announce its full year results for the year ended 31 December 2019. Financial Highlights Open Orphan plc (As reported) hVIVO plc (As reported) Open […]
Open Orphan #ORPH – Testing of anti-viral for treating COVID-19 underway
Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that its London-based subsidiary hVIVO has commenced the testing of an anti-viral for treating COVID-19 on behalf of […]
Open Orphan #ORPH – Completion of the compulsory acquisition of remaining hVIVO shares
Open Orphan (ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, announces that further to the announcement of 28 January 2020, the Company will shortly be posting letters to shareholders of hVIVO plc […]
Shares Magazine Spotlight – Open Orphan lining up for coronavirus fight
LSE interview – Cathal Friel refocuses Open Orphan #ORPH as he raises 5m and buys virology specialist hVIVO
In a wide-ranging interview with London South East, Open Orphan Executive Chairman Cathal Friel outlines his vision for the business and explains how the combined talents of Open Orphan, hVivo and Venn Life Sciences will create a soon to be profitable pharmaceutical services one-stop shop. Friel says this acquisition is the last however, as he […]
Open Orphan #ORPH presents at Shares Growth and Invention Forum, London
Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that the Company will be attending and presenting at the Shares Growth and Invention Forum on February 11, 2020 at Business Design […]
Open Orphan #ORPH – Upcoming Investor Events
Open Orphan (ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that the Company will be attending and presenting at a series of investor events from the 11th February […]
Proactive Investors interview with the Open Orphan #ORPH team on its future and ‘the lottery ticket’ sitting within hVIVO
Open Orphan PLC‘s (LON:ORPH) Cathal Friel speaks to Proactive London’s Andrew Scott following the completion last week of its £5.3mln fundraise. Also in studio is adviser to Open Orphan and founder of hVivo Professor John Oxford. Professor Oxford’s been a leader in the field of vaccine and anti-viral clinical trials for the last 20 years. […]
BRR Media – Open Orphan #ORPH business update
Cathal Friel, Executive Chairman of Open Orphan, provides an update on developments at the company following the successful fundraising, and also introduces Professor John Oxford – a leading expert in the field of virology and an original founder of hVIVO – who will be working with the company as a consultant.